	US 12,281,363 B2
	Methods for detecting antiviral-drug resistant virus
Jean Lutamyo Mbisa, London (GB)
Assigned to Secretary of State for Health and Social Care, London (GB)
Appl. No. 15/734,910
Filed by Secretary of State for Health and Social Care, London (GB)
PCT Filed Jun. 4, 2019, PCT No. PCT/GB2019/051546 § 371(c)(1), (2) Date Dec. 3, 2020, PCT Pub. No. WO2019/234413, PCT Pub. Date Dec. 12, 2019.
Claims priority of application No. 1809135 (GB), filed on Jun. 4, 2018.
Prior Publication US 2021/0230710 A1, Jul. 29, 2021
Int. Cl. C12Q 1/68 (2018.01); C12Q 1/70 (2006.01); G01N 33/569 (2006.01)

CPC C12Q 1/705 (2013.01) [G01N 33/56994 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01); G01N 2800/52 (2013.01)]

6 Claims

1. A method of detecting a variant Herpes simplex virus 1 (HSV-1) thymidine kinase (TK) in a biofluid sample, comprising:

a. obtaining a biofluid sample from a patient; and

b. detecting a variant HSV-1 TK 100C>T mutation present in the biofluid sample, by amplifying the variant HSV-1 TK gene, or fragment thereof using a set of primers to produce amplified nucleic acids, sequencing the amplified nucleic acids, and detecting said variant HSV-1 TK gene, or fragment thereof; or

c. detecting a variant HSV-1 TK Q34* (Q34STOP mutation) present in the biofluid sample by performing mass spectrometry, a Western Blot, an Enzyme activity assay and/or an Enzyme-Linked Immunosorbent Assay (ELISA).